EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Clinical Trials Contact
- Telefoonnummer: 412-330-6151
- E-mail: ctgov@ahn.org
Studie Locaties
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- AHN Allegheny General Hospital
-
Contact:
- Clinical Trials Contact
- Telefoonnummer: 4123306151
- E-mail: ctgov@ahn.org
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Nog niet aan het werven
- AHN Allegheny General Hospital
-
Contact:
- Clinical Trials Contact
- Telefoonnummer: 412-330-6151
- E-mail: ctgov@ahn.org
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance by a CSCS
- Must be able to read and understand English and consent for themselves.
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Beta blocker or GLP-1 inhibitor medications
- Pregnant women
- Males
- Lactose intolerance
- Cow's milk or whey protein allergy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: 60 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle). |
60 grams of whey protein |
|
Experimenteel: 0 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle). |
0 grams of whey protein |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Determine changes in pounds of muscle and fat mass after each exercise regimen
Tijdsspanne: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimen
Tijdsspanne: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free mass
Tijdsspanne: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in Y-balance score at the completion of the exercise regimen
Tijdsspanne: Baseline and at program completion (within 4 weeks of exercise completion)
|
Y-Balance score measures the length an individual can extend their foot. The larger the score the better the balance. |
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Functional Movement Screen (FMS) scores at the completion of the exercise regimen
Tijdsspanne: Baseline and at program completion (within 4 weeks of exercise completion)
|
FMS measures movement patterns with scoring from 0 to 21. The large the score the better the mobility. |
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Determine changes in phase angle at the completion of the exercise regimen
Tijdsspanne: At program completion (at 8 weeks)
|
Phase angle measures the fluidity of cells and the larger the value the better. |
At program completion (at 8 weeks)
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Colin Champ, MD, CSCS, AHN Radiation Oncology
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Huidziektes
- Borst ziekten
- Gedrag
- Huid- en bindweefselaandoeningen
- Neoplasmata
- Borstneoplasmata
- Motorische activiteit
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Voedsel
- Dieet, voedsel en voeding
- Fysiologische fenomenen
- Eten en dranken
- Zuivelproducten
- Melk
- Dieetproteïnen
- Melkproteïnen
- Dierlijke eiwitten, dieet
- Wei
- Wei -eiwitten
Andere studie-ID-nummers
Andere studie-ID-nummers
- 2026-159-SG
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .